top of page

【Portfolio】Anji Pharma Adds Clinical Sites to Accelerate Clinical Development of Pradigastat for the Treatment of Functional Constipation

封面logo2.35-1-anji.png

View source version on https://anjipharma.com/news/anji-pharma-adds-clinical-sites-to-accelerate-clinical-development-of-pradigastat-for-the-treatment-of-functional-constipation/

15 Apr 2021


A “Truly Global” Development Strategy Keeps Phase 2 Program on Track Amidst Worldwide Pandemic

CAMBRIDGE, Mass. and SHANGHAI – Anji Pharma has initiated dosing in the U.S. and China as part of a Phase 2 program for pradigastat (ANJ908) in functional constipation. Pradigastat, a first-in-class inhibitor of diacylglycerol acyl transferase 1 (DGAT1), has a robust safety and pharmacodynamic profile that has been rigorously established across multiple clinical studies.

Chronic constipation affects nearly one in seven Americans, with nearly two million patients seeking pharmacotherapy options worldwide. In addition to functional constipation, related conditions where pradigastat may have clinical benefit include irritable bowel syndrome-associated and opioid-induced constipation.

“Despite the prevalence of chronic constipation, current treatment options are desperately lacking, with low response rates typical for all approved medications,” said Dan Meyers, M.D., Chief Medical Officer of Anji. “Based on our analysis of existing clinical data, we anticipate pradigastat will offer patients and physicians a significantly higher response rate, and we look forward to sharing the data as it becomes available.”

To accelerate bringing medicines to patients across the globe, Anji has synchronized development in North America and Asia to allow new drug application (NDA) filings in near-simultaneous fashion across major markets. Anji’s Phase 2 study with pradigastat will enroll approximately 180 patients at clinical sites in U.S. and China. Patients will receive pradigastat tablets (20 or 40 mg) or placebo once daily for four weeks and evaluated for improvements in constipation measures (ClinicalTrials.gov Identifier NCT04620161).

Anji holds pradigastat development and commercial rights for constipation-related disorders in all global markets, including U.S., Europe, and Asia.

About Anji Pharma

Anji Pharma is a clinical-stage company dedicated to bringing life-changing therapies to patients as efficiently as possible.  Taking inspiration from its namesake bridge in Hebei Province, Anji strives to “Aid Those in Need,” while building connectivity across patient-centric ecosystems.  In addition to pradigastat, Anji is developing delayed-release metformin (ANJ900) for effective glucose management in patients with type 2 diabetes and advanced chronic kidney disease.  Global pivotal trials for ANJ900 are expected to initiate by mid-2021.

This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security; nor does it constitute an offer to provide investment advisory or other services by Viva Ventures Biotech Fund or any of our affiliates. Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, Viva Ventures Biotech has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed on this website by Viva Ventures biotech were prepared based upon information, believed to be reliable, available to it at the time such views were written. Viva Ventures Biotech makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, the reader agrees that he/she not copy, reproduce, republish, upload, post, transmit, alter, or distribute in any way material from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of Viva Ventures Biotech.

bottom of page